By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merrion Pharmaceuticals, Inc. 

3013 Lake Drive
Citywest Business Campus
Dublin    24  Ireland
Phone: +353-1-469-3719 Fax:


Merrion Pharmaceuticals is engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection.




Founder: Michael Donnelly

CEO: John Fox

CSO (Scientific): Thomas Leonard

Key Statistics

Ownership: Private

Web Site: Merrion Pharma


Company News
Merrion Pharma Looks to Wind Up Operations, Announces Liquidation Plans 8/23/2016 6:05:11 AM
Merrion Pharmaceuticals, Inc. Bids To Attract €52m Investment For Products 12/1/2014 6:05:57 AM
Hovione And Merrion Pharmaceuticals, Inc. Announce Strategic Partnership On Use Of Merrion's GIPET Technology 7/15/2014 9:26:39 AM
Merrion Pharmaceuticals, Inc. to Cut 20 Dublin Jobs 9/2/2011 8:07:24 AM
Merrion Pharmaceuticals, Inc. and Novo Nordisk A/S (NVO) Sign EUR 1.5M Deal for Oral Formulation Technology 12/22/2010 8:10:16 AM
Merrion Pharmaceuticals, Inc. Signs Feasibility and Option Agreement for 3 Drugs With International 'Top Ten' Pharmaceutical Company 12/6/2010 11:07:49 AM
Merrion Pharmaceuticals, Inc. Announces Commencement of Feasibility and Option Agreement With Rebel Pharmaceuticals 11/23/2010 11:20:48 AM
Merrion Pharmaceuticals, Inc. Finalises Its Phase III Development Program for Orazol(TM) in the USA 11/16/2010 9:40:59 AM
Merrion Pharmaceuticals, Inc. is Issued a Key U.S. Patent for Orazol(TM), Their Lead Product to Treat Bone Metastases Associated With Prostate, Breast and Other Cancers 5/7/2010 9:52:26 AM
Merrion Pharmaceuticals, Inc. is Issued a Key United States Patent 3/2/2010 8:33:46 AM